3-Aminobenzamide

3-Aminobenzamide

SCHEMBL10277410

NC(=O)c1cccc(N)c1.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.55
PARP1 P09874 7/20 0.52
PTGS1 P23219 3/20 0.48
F2 P00734 1/20 0.47
PLG P00747 1/20 0.47
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
TSHR P16473 3/20 0.47
POLB P06746 2/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C19 P33261 1/20 0.47
RECQL P46063 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL10277408 0.89 PARP1 (0.59) PARP1TSHRPOLBCYP3A4MAPT
Trifluoroacetic Acid SCHEMBL29713373 0.89 PARP1 (0.59) PARP1TSHRPOLBCYP3A4MAPT
3-Aminobenzamide SCHEMBL16070 0.87 PBRM1 (0.63) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL27679552 0.87 PBRM1 (0.63) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL28015741 0.85 PBRM1 (0.61) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL8688920 0.85 F2 (0.63) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL28944114 0.85 PBRM1 (0.61) PBRM1PARP1F2PLGPRSS1
Terephthalic Acid SCHEMBL28053568 0.81 PBRM1 (0.58) PBRM1PARP1F2PLGPRSS1
Trifluoroacetic Acid SCHEMBL7759604 0.81 DHODH (0.58) PARP1PRSS1PRSS2PRSS3TSHR
Trifluoroacetic Acid SCHEMBL30687977 0.81 DHODH (0.58) PARP1PRSS1PRSS2PRSS3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590942-B1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2016-05-04 EP disclosed
US-9079880-B2 Rho kinase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-07-14 US disclosed
EP-2590942-A1 RHO KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2013-05-15 EP disclosed
US-20120178752-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-07-12 US disclosed
WO-2012006202-A1 RHO KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178752-A1 RHO KINASE INHIBITORS ROCK1, ROCK2, RHOA PBRM1 2888/4885PARP1 1130/4885PTGS1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.